Do elevations in Troponin I and C-Reactive Protein predict congestive heart failure in breast cancer patients treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib?
In breast cancer patients receiving dose-dense chemotherapy with trastuzumab and lapatinib, troponin I elevations are common and may precede LVEF declines, but they do not reliably predict clinical congestive heart failure.
In patients receiving ddAC → PTL, cTnIs are commonly detected. These elevations may precede changes in LVEF but, as assessed in this trial, do not predict CHF.
Morris et al. (Fri,) studied this question.